Zhiyu Wang

Shijiazhuang, 050011, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Standardized Construction of Lung Cancer Organoids and Their Application Progress  in the Precise Treatment of Lung Cancer

Standardized Construction of Lung Cancer Organoids and Their Application Progress  in the Precise Treatment of Lung Cancer

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: August 24, 2026

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Journal: JAMA

Published: June 17, 2026

A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion.

A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion.

Journal: International journal of cancer

Published: May 21, 2025

Extracellular vesicles from prostate tumors reshape the pre-metastatic bone environment in an mTOR/RAB1A-dependent manner.

Extracellular vesicles from prostate tumors reshape the pre-metastatic bone environment in an mTOR/RAB1A-dependent manner.

Journal: Frontiers in immunology

Published: April 03, 2025

pH-Activated Nanoplatform Derived from M1 Macrophages' Exosomes for Photodynamic and Ferroptosis Synergistic Therapy to Augment Cancer Immunotherapy.

pH-Activated Nanoplatform Derived from M1 Macrophages' Exosomes for Photodynamic and Ferroptosis Synergistic Therapy to Augment Cancer Immunotherapy.

Journal: Biomaterials research

Published: November 08, 2024

Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy.

Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy.

Journal: Frontiers in immunology

Published: November 02, 2024

Lipid Nanoparticular Codelivery System for Enhanced Antitumor Effects by Ferroptosis-Apoptosis Synergistic with Programmed Cell Death-Ligand 1 Downregulation.

Lipid Nanoparticular Codelivery System for Enhanced Antitumor Effects by Ferroptosis-Apoptosis Synergistic with Programmed Cell Death-Ligand 1 Downregulation.

Journal: ACS nano

Published: June 13, 2024

Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.

Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.

Journal: JAMA

Published: May 31, 2024

Acidity-activatable dynamic hybrid nanoplatforms derived from extracellular vesicles of M1 macrophages enhance cancer immunotherapy through synergistic triple immunotherapy.

Acidity-activatable dynamic hybrid nanoplatforms derived from extracellular vesicles of M1 macrophages enhance cancer immunotherapy through synergistic triple immunotherapy.

Journal: Journal of nanobiotechnology

Published: March 11, 2024

Cell Membrane Hybrid Lipid Nanovesicles Enhance Innate Immunity for Synergistic Immunotherapy by Promoting Immunogenic Cell Death and cGAS Activation.

Cell Membrane Hybrid Lipid Nanovesicles Enhance Innate Immunity for Synergistic Immunotherapy by Promoting Immunogenic Cell Death and cGAS Activation.

Journal: Biomaterials research

Published: January 13, 2024

Novel Association of RAD54L Mutation with Müllerian Clear Cell Carcinoma of the Male Urethra: New Insights Regarding the Molecular Mechanisms of a Rare Tumour.

Novel Association of RAD54L Mutation with Müllerian Clear Cell Carcinoma of the Male Urethra: New Insights Regarding the Molecular Mechanisms of a Rare Tumour.

Journal: Current cancer drug targets

Published: May 05, 2023

An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.

An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.

Journal: Journal of Cancer

Published: March 20, 2023

Showing 1-12 of 32

Last Updated: 09/26/2026